Floatz logo

MUREPAVADIN

Lower Respiratory Infection

Polyphor Ltd.protein_peptidePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Lower Respiratory Infection cohort.

Asset / SponsorPhaseRating
Piperacillin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
Tazobactam
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
Ciprofloxacin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4B
PREDNISONE TABLETS
Maisonneuve-Rosemont Hospital
Phase 2CCC
Azithromycin
Maisonneuve-Rosemont Hospital
Phase 2CCC

View all 13 →

Same molecule, other indications

MUREPAVADIN is also rated in:

bronchiectasisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →